Prediction: Lilly Will Trade at $1,200 by Year-End
Investors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
Benchmarks provide objective yardsticks to assess results, set expectations, and keep portfolios aligned with objectives.
20,321 articlesInvestors weigh a bold forecast that Eli Lilly could hit $1,200 by year-end 2026, betting on GLP-1 drugs and a robust...
As GBTC’s 1.50% fee persists, the cost compounds for long-horizon investors. This piece compares the drag to cheaper ...
FOMO meets fundamentals. This guide breaks down how to evaluate a space tech megacap, manage risk, and decide if mont...
In June 2026, Bitcoin traders face a new threat: boredom. CryptoQuant sees a protracted lull in demand as the real ri...
Bitcoin and wider crypto markets are eyeing a massive options expiry as traders lean into volatility bets. The option...
Tether earns money mainly from interest on the reserves backing USDT. As market yields rise and policy moves shift, t...
SpaceX often grabs headlines, but the case for buying stock today isn’t as clear-cut. Here are three solid cautions t...
Investors are weighing a mid-year drop in Booking Holdings against solid fundamentals. This guide explains how to ass...
A strategic expansion at Energy Transfer's Nederland NGL Export Terminal aims to boost export capacity and support a ...
Fans are buzzing for GTA 6, but scammers are buzzing louder. This article reveals how a 'beta invite promises early' ...
SpaceX’s blockbuster IPO propelled Elon Musk into a trillion-dollar spotlight. This piece explains what the milestone...
Pennymac confirms it will shutter its Franklin, TN office and reduce staff in its consumer direct lending unit, part ...